News

Public · Published

Stryker 3Q 2026: Revenue $6.52B, Net income $753M, EPS $1.96— 10-Q Summary

Stryker reported third-quarter 2026 revenue of $6.52B, up 7.6% from a year earlier, while net income fell 12.3% to $753M and diluted EPS dropped 11.7% to $1.96. Sales rose on higher unit volumes across several businesses.

Published:

Updated:

What happened

Stryker reported third-quarter 2026 revenue of $6.52B, up 7.6% from a year earlier, while net income fell 12.3% to $753M and diluted EPS dropped 11.7% to $1.96. Sales rose on higher unit volumes across several businesses.

Confirmed

Global impact / market context

Sales grew while profit fell, so more revenue did not translate into more earnings per share. That gap can pressure the stock because investors pay for profit growth, and it raises questions about costs and the mix of products Stryker sells.

Analyst inference

Management expects faster growth in lower-margin MedSurg and Neurotechnology, which means more sales may come with thinner profit per sale. Supply constraints and cybersecurity disruption add operational risk, so investors will weigh growth against earnings quality and execution.

Analyst inference

What to watch

  1. Watch whether MedSurg and Neurotechnology keep growing faster than Orthopaedics, since management expects that mix shift toward lower-margin businesses to continue. Confirmed
  2. Track the cost drivers behind the profit decline, because revenue rose 7.6% while net income fell 12.3%, a gap that suggests higher expenses or a less profitable sales mix. Analyst inference
  3. Monitor supply constraints and cybersecurity disruption, which the article names as operational risks that could affect Stryker's ability to deliver products and record sales. Confirmed

Evidence

  • Original source link unavailable